Details for New Drug Application (NDA): 206162

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

NDA 206162 describes LYNPARZA, which is a drug marketed by Astrazeneca and is included in two NDAs. It is available from one supplier. There are eleven patents protecting this drug. Additional details are available on the LYNPARZA profile page.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olaparib profile page.

Summary for 206162

Tradename:	LYNPARZA
Applicant:	Astrazeneca
Ingredient:	olaparib
Patents:	7

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for 206162

Generic Entry Date for 206162^: See Plans and Pricing* Constraining patent/regulatory exclusivity: See Plans and Pricing Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	CAPSULE;ORAL			Strength	50MG
Approval Date:	Dec 19, 2014	TE:		RLD:	Yes
Patent:	See Plans and Pricing	Patent Expiration:	Apr 29, 2022	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patent:	See Plans and Pricing	Patent Expiration:	Oct 11, 2024	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patent:	See Plans and Pricing	Patent Expiration:	Oct 11, 2024	Product Flag?	Y	Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 206162

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	LYNPARZA	olaparib	CAPSULE;ORAL	206162-001	Dec 19, 2014	See Plans and Pricing	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for 206162

DrugPatentWatch® Estimated Generic Entry Opportunity Date for 206162

Profile for product number 001

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for 206162